|Day Low/High||86.77 / 87.80|
|52 Wk Low/High||74.97 / 96.31|
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: APLP, DCI, DWRE, ISIL, MBT, NVS, STC Downgrades: AMG, COH, EQS, GIG, LECO, MITK, NEWM, TRNC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Trade-Ideas LLC identified Novartis (NVS) as a pre-market leader candidate
Stay away from banks, but pharmaceuticals and tech stocks look good, analysts say.
It was all about the green at this week's Cannabis World Congress in New York.
The rally has been strong and the bull market is taking a deserved rest, Cramer says.
TheStreet highlights 3 stocks pushing the health care sector lower today.
Here's the lowdown on the biotech companies that have come public this year.
Novartis has had to cope with the expiration of some patents, but it should benefit from its varied products and significant investment in research and development.
Problems with mesh products and high leverage might scare away a potential buyer.
Shares of Valeant Pharmaceuticals jumped following last night's report by The Wall Street Journal saying that the company rejected a joint takeover approach from Takeda Pharmaceuticals and TGP Capital.
Trade-Ideas LLC identified Novartis (NVS) as a pre-market mover with heavy volume candidate
Ziopharm is its own mini biotech bubble, held aloft unjustifiably because of its interlocking relationship with Intrexon, the synthetic biology company majority-owned by R.J. Kirk.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
AstraZeneca, Bayer, Eli Lilly and Merck are just a few of the names that may join a bidding war for the cancer drug maker, analysts say.
New Chairman and CEO Joe Papa can't stop the world from gunning for Valeant.
TheStreet's founder shares his thoughts after his one-on-one interview with Valeant's new chairman and CEO.
The drug industry is getting pilloried in the court of public opinion, but that only creates buying opportunities for you.
The San Francisco target rejects the $9.3 billion offer, but biotech growth and a healthy pipeline mean Sanofi isn't desperate for Medivation's cancer treatments.
U.S. stock futures slide Monday while European and Asian shares slump ahead of rate-setting meetings this week of the Federal Reserve and the Bank of Japan.
The failure of OPEC's latest attempts to hammer out an oil production freeze is likely to have dire consequences for global equity markets.
European stocks stabilize on Wednesday, with health care stocks among the gainers as Pfizer reportedly prepares to announce the termination of its $160 billion deal for Allergan.
Renewed worries over the Federal Reserve's rate hike plans and another selloff in crude oil prices team up to beat down Wall Street in a sour start to the week.
Stocks extend their decline by mid-afternoon Monday on renewed worries the Federal Reserve could raise rates sooner than Wall Street anticipates.
Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top 10 biopharmaceutical brands.
Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top ten biopharmaceutical brands.
TheStreet highlights 3 stocks pushing the drugs industry lower today.
Trade-Ideas LLC identified Novartis (NVS) as a pre-market laggard candidate
Seven companies in the S&P 500 have no women on their boards. Maybe they're having trouble finding the right women? We aren't. Here are 10 that would make great additions.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.